Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Committed To Third-Party Review, Henney Tells Senate HELP Committee

This article was originally published in The Gray Sheet

Executive Summary

FDA Commissioner Jane Henney is "puzzled" about the low utilization rate within the device industry of the agency's "Accredited Persons" third-party premarket review program, she said at an Oct. 21 Senate Health, Education, Labor and Pensions Committee hearing.

You may also be interested in...



User Fees In Administration's Budget Request Aimed At Third-Party Program

FDA's Center for Devices and Radiological Health is hoping that the most recent user fee proposal set forth in the administration's FY 2001 budget request might breathe some life into the agency's moribund 510(k) third-party review program.

User Fees In Administration's Budget Request Aimed At Third-Party Program

FDA's Center for Devices and Radiological Health is hoping that the most recent user fee proposal set forth in the administration's FY 2001 budget request might breathe some life into the agency's moribund 510(k) third-party review program.

CDRH QSIT Team Considers Third-Party Audit Option To Level 1 Inspections

Firms with a good compliance history may be eligible to submit third-party auditing certifications in lieu of biennial FDA inspections, according to a proposal being drafted for consideration by the Center for Devices and Radiological Health's quality systems inspection technique (QSIT) reengineering team.

Related Content

UsernamePublicRestriction

Register

MT012479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel